- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Standardizing Stroke Care to Improve Outcomes and Reduce Costs
Researchers at the University of Michigan Medical School have developed a map of the United States highlighting significant variation in stroke care.
Researchers at the University of Michigan Medical School have developed a quilted map of the United States highlighting the tremendous variation in stroke care in need of standardization. Published this month in the journal Stroke, the study points to the huge variation in the use of the "clotbuster" drug tissue plasminogen activator (tPA), which if administered within the first few hours of a stoke can restore blood supply to the brain. This can avoid potential disabilities and lower long-term costs of care in the patients.
The population used in the study were Medicare enrollees who had suffered from a stroke and were admitted through Emergency Rooms in one of 3436 hositals surveyed in the study between 2007 and 2010. In 20% of the geographical regions where these hospitals were located, patients did not receive tPA. Of the 844,241 admissions resulting from ischemic stroke, 3.7% of patients were administered tPA and only 0.5% received intra-arterial stroke treatment, with or without tPA.
A senior author on the study believes understanding the causes of the variation and addressing them would have a significant impact on stroke-associated disability.
Read more on EurekAlert!
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
